ATP1A1
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Colorectal cancer.
Overview
Catalytic subunit of the Na(+)/K(+)-ATPase pump that hydrolyses ATP to exchange ions across the plasma membrane, exporting 3 Na(+) and importing 2 K(+) per cycle against electrochemical gradients. It undergoes ATP-driven conformational changes that allow alternating binding and release of Na(+) and K(+) ions across the membrane. This process maintains essential Na(+) and K(+) gradients for membrane potential and cellular function.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes clinical 0.18, affected pathway 0.32, literature 0.95, genetic association 0.00, somatic mutation 0.77). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Invasive Breast Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Colorectal cancer.
- 1 · What it is
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Colorectal cancer.
- 2 · What goes wrong in cancer
Catalytic subunit of the Na(+)/K(+)-ATPase pump that hydrolyses ATP to exchange ions across the plasma membrane, exporting 3 Na(+) and importing 2 K(+) per cycle against electrochemical gradients.
- 3 · How drugs use it
No product in this corpus aims at ATP1A1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:799 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P05023 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000163399 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: colorectal cancer 0.50, gastric cancer 0.51 (GraphQL API, CC0)); IntOGen ATP1A1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Catalytic subunit of the Na(+)/K(+)-ATPase pump that hydrolyses ATP to exchange ions across the plasma membrane, exporting 3 Na(+) and importing 2 K(+) per cycle against electrochemical gradients. It undergoes ATP-driven conformational changes that allow alternating binding and release of Na(+) and K(+) ions across the membrane. This process maintains essential Na(+) and K(+) gradients for membrane potential and cellular function. Could also be part of an osmosensory signalling pathway that senses body-fluid sodium levels and controls salt intake behaviour as well as voluntary water intake to regulate sodium homeostasis. Location: Cell membrane; Basolateral cell membrane; Cell membrane, sarcolemma; Cell projection, axon (UniProt). Locus 1p13.1 (HGNC).
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056)
- Colorectal cancer: Open Targets association 0.50 with colorectal cancer (MONDO_0005575)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.18; IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ATP1A1" OR ABSTRACT:"ATP1A1" OR TITLE:"ATPase Na+/K+ transporting subunit alpha 1" OR ABSTRACT:"ATPase Na+/K+ transporting subunit alpha 1" OR TITLE:"Sodium/potassium-transporting ATPase subunit alpha-1" OR ABSTRACT:"Sodium/potassium-transporting ATPase subunit alpha-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATP1A1, not a curated reading list.